Althea Technologies Inc. announced today that it has extended its service offering to include labeling, packaging, storage, and distribution of drug and biological products through its co-marketing partner, Sherpa Clinical Packaging. Sherpa, founded in 2011, is located adjacent to Althea's clinical and commercial-scale biologics and drug product manufacturing facilities. The proximity of the facilities to one another simplifies supply chain logistics for clients of each organization.
Pharma Tech Industries (Royston, GA; PTI) recently completed the construction of a cleanroom dedicated to pouch filling of powder-based products. The room was built specifically to house the new high-speed Oystar Jones Adjustable Pouch King. The machine will fill pouches for multiple powder-based products including a cholesterol medication and laxative granular powder.
Almac’s Pharma Services business has expanded its commercial facility by adding increased storage capacity for biologic products. The company has experienced increased client demand for cold and dedicated frozen storage capacity for biopharmaceuticals, so it added an additional 6124 sq ft of cold and frozen storage.
Demand for prefilled syringes continues to grow, reports Yves Buelens, general manager of Catalent Pharma Solutions’ (www.catalent.com) Sterile Technologies facility in Brussels, Belgium. Catalent offers a wide range of services to the pharmaceutical industry from drug development through clinical and commercial manufacturing and packaging services. Catalent processed a large number of prefilled syringes in 2009 on its three filling lines in Brussels, and the firm is poised to add a fourth line.
Catalent Pharma Solutions is celebrating the 50th anniversary of its Schorndorf, Germany, facility specializing in modified release technologies and clinical supply services.
Almac’s new North American Headquarters facility can now handle packaging, storage, and distribution of Schedule I – V controlled substances. Situated in Souderton, PA, the facility is nearing the end of its phased transition fueled by a $120 million investment.
Occupying a total of 3980 square feet, storage for controlled materials is located in a highly secured temperature-monitored cage and vault. Both locations meet DEA requirements as well as provide substantially greater capacity.